case_images: PMC10261696_01
case_images: Maximum Projection Image (MIP) of the patient on Baseline PET/CT (a) reveal tracer uptake in multiple vertebrae, Interim PET/CT MIP image (b) reveals increased tracer uptake in vertebrae, MIP image on End Cycle PET/CT (c) reveal negligible uptake in the corresponding vertebrae
case_images: AOJNMB-02-175-g001.jpg
case_images: PMC10261696_01_AOJNMB-02-175-g001.jpg
case_images: F1
case_images: The whole body FDG PET scan (Figure 1-2) showed metabolically active regional and other non-regional lymph nodes and multiple skeletal metastases in Dorso-lumbar vertebrae. However, the skeletal lesions show increased FDG uptake (Figure 1-2). She received four cycles of chemotherapy and underwent an end-of-treatment FDG PET/CT scan for response evaluation (Figure 1-2).
case_images: The initial FDG PET scan (Figure 1a-maximum intensity projection [MIP], 2a- sagittal fused PET-CT, 2d- sagittal CT) showed metabolically active mediastinal, right axillary, right supraclavicular, cervical, and retroperitoneal lymph nodes with extensive skeletal lesions. Interim FDG PET scan (Figure 1b-MIP, 2b-sagittal fused PET-CT) showed an increase in the FDG uptake and the SUVmax in the D7 (Green arrow), L1 (Red arrow), and L5 (Blue arrow) vertebrae. The SUVmax for vertebral lesions was 4.2, 5.7, and 6.5, respectively. Above mentioned corresponding vertebral lesions shows lytic -sclerotic changes on the CT (Figure 2e, Sagittal CT). The patient underwent an end of cycle FDG PET scan (Figure 1c-MIP, 2c-sagittal fused PET-CT) after four more cycles of chemotherapy. There was no significant FDG avidity in the previously noted lesion. Dense sclerotic changes were noted on CT (Figure 2f-sagittal CT)
case_images: AOJNMB-02-175-g002.jpg
case_images: PMC10261696_01_AOJNMB-02-175-g002.jpg
case_images: F2
case_images: The whole body FDG PET scan (Figure 1-2) showed metabolically active regional and other non-regional lymph nodes and multiple skeletal metastases in Dorso-lumbar vertebrae. However, the skeletal lesions show increased FDG uptake (Figure 1-2). She received four cycles of chemotherapy and underwent an end-of-treatment FDG PET/CT scan for response evaluation (Figure 1-2).